JFG
BCRX icon

Jefferies Financial Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Jefferies Financial Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-262,465
Closed -$1.99M – 1857
2025
Q3 		$1.99M Buy
262,465
+95,888
+58% +$798K 0.01% 644
2025
Q2 		$1.49M Buy
+166,577
New +$1.55M 0.01% 610
2023
Q3 		– Sell
-65,000
Closed -$458K – 1625
2023
Q2 		$458K Buy
+65,000
New +$522K ﹤0.01% 1207

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jefferies Financial Group's BCRX Position: Q4 2025 in Review

Jefferies Financial Group sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 262,465 shares — an estimated $1.99M sold.

Jefferies Financial Group first reported a position in BCRX in Q2 2023 and held it in 3 quarters. The position peaked at $1.99M in Q3 2025. 273 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

  • Jefferies Financial Group reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Jefferies Financial Group sold 262,465 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $1.99M.
  • Jefferies Financial Group first reported a position in BioCryst Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Jefferies Financial Group's BioCryst Pharmaceuticals position peaked at $1.99M in Q3 2025.
  • 273 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Jefferies Financial Group's 13F filing for Q4 2025, filed 9 Feb 2026.